Hematopoietic transplants for disease suppression and cure in type 1 diabetes

Current Stem Cell Research and Therapy

Volumn 8, Issue 4, 2013, Pages 333-339

  Askenasy, Nadir ^a  

^a SCHNEIDER CHILDREN S MEDICAL CENTER OF ISRAEL   (Israel)

Author keywords

Activation induced cell death; Autoimmunity; Fas cross linking; Inflammation; Regulatory T cells

Indexed keywords

C PEPTIDE; CYCLOPHOSPHAMIDE; GLYCOSYLATED HEMOGLOBIN; GUANOSINE TRIPHOSPHATASE; THYMOCYTE ANTIBODY;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; APOPTOSIS; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNITY; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CELL DESTRUCTION; DISEASE COURSE; DISEASE EXACERBATION; FOLLOW UP; GLUCOSE HOMEOSTASIS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; INSULIN DEPENDENT DIABETES MELLITUS; LYMPH NODE IRRADIATION; LYMPHOCYTE PROLIFERATION; LYMPHOCYTOPENIA; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE; THERAPY EFFECT; TREATMENT OUTCOME;

ANIMALS; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 1; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSION; TREATMENT OUTCOME;

EID: 84888097082     PISSN: 1574888X     EISSN: None     Source Type: Journal    
DOI: 10.2174/1574888X113089990001     Document Type: Article

References (111)

1. Alderuccio F, Siatskas C, Chan J, Field J, Murphy K, Nasa Z, Toh BH. Haematopoietic stem cell gene therapy to treat autoimmune disease. Curr Stem Cell Res Ther 2006; 1: 279-87
2. Burns CJ, Persaud SJ, Jones PM. Diabetes mellitus: a potential target for stem cell therapy. Curr Stem Cell Res Ther 2006; 1: 255-66.
3. Couri CE, Voltarelli JC. Stem cell-based therapies and immunomodulatory approaches in newly diagnosed type 1 diabetes. Curr Stem Cell Res Ther 2011; 6: 10-5.
4. LoCascio SA, Spinelli J, Kurtz J. Hematopoietic stem cell transplantation for the treatment of autoimmunity in type 1 diabetes. Curr Stem Cell Res Ther 2011; 6: 29-37.
5. Brodsky RA, Jones RJ. Intensive immunosuppression with high dose cyclophosphamide but without stem cell rescue for severe autoimmunity: advantages and disadvantages. Autoimmunity 2008; 41: 596-600.
6. Hanafusa T, Miyagawa J, Nakajima H, Tomita K, Kuwajima M, Matsuzawa Y, Tarui S. The NOD mouse. Diabetes Res Clin Pract 1994; 24(Suppl): S307-11.
7. Delovitch TL, Singh B. The nonobese diabetic mouse as a model of autoimmune diabetes: immune dysregulation gets the NOD. Immunity 1997; 7: 727-38.
8. Anderson MS, Bluestone JA. The NOD mouse: a model of immune dysregulation. Annu Rev Immunol 2005; 23: 447-85.
9. Driver JP, Serreze DV, Chen YG. Mouse models for the study of autoimmune type 1 diabetes: a NOD to similarities and differences to human disease. Semin Immunopathol 2011; 33: 67-87.
10. Rossini AA, Slavin S, Woda BA, Geisberg M, Like AA, Mordes JP. Total lymphoid irradiation prevents diabetes mellitus in the Bio-Breeding/Worcester (BB/W) rat. Diabetes 1984; 33: 543-7.
11. Strober S, Fariñas MC. Cellular mechanisms in immune tolerance and treatment of autoimmune disease: Studies using total lymphoid irradiation (TLI). J Autoimmun 1988; 1: 693-702.
12. Beilhack GF, Scheffold YC, Weissman IL, et al. Purified allogeneic hematopoietic stem cell transplantation blocks diabetes pathogenesis in NOD mice. Diabetes 2003; 52: 59-68.
13. Kaminitz A, Mizrahi K, Yaniv I, Farkas DL, Stein J, Askenasy N. Low levels of allogeneic but not syngeneic hematopoietic chimerism reverse autoimmune insulitis in prediabetic NOD mice. J Autoimmun 2009; 33: 83-91.
14. Bagley J, Tian C, Sachs DH, Iacomini J. T cells mediate resistance to genetically modified bone marrow in lethally irradiated recipients. Transplantation 2002; 74: 1454-60.
15. Colucci F, Cilio CM, Lejon K, Goncalves CP, Bergman ML, Holmberg D. Programmed cell death in the pathogenesis of murine IDDM: resistance to apoptosis induced in lymphocytes by cyclophosphamide. J Autoimmun 1996; 9: 271-6.
16. Steptoe RJ, Stankovic S, Lopaticki S, Jones LK, Harrison LC, Morahan G. Persistence of recipient lymphocytes in NOD mice after irradiation and bone marrow transplantation. J Autoimmun 2004; 22: 131-8.
17. Masopust D, Vezys V, Marzo AL, Lefrancois L. Preferential localization of effector memory cells in nonlymphoid tissue. Science. 2001; 291: 2413-7.
18. Masopust D, Vezys V, Usherwood EJ, et al. Activated primary and memory CD8 T cells migrate to nonlymphoid tissues regardless of site of activation or tissue of origin. J Immunol 2004; 172: 4875-82.
19. Marzo AL, Yagita H, Lefrançois L. Cutting edge: migration to nonlymphoid tissues results in functional conversion of central to effector memory CD8 T cells. J Immunol 2007; 179: 36-40.
20. Franke DD, Yolcu ES, Alard P, Kosiewicz MM, Shirwan H. A novel multimeric form of FasL modulates the ability of diabetogenic T cells to mediate type 1 diabetes in an adoptive transfer model. Mol Immunol 2007; 44: 2884-92.
21. Kaminitz A, Yolcu ES, Askenasy EM, et al. Effector and naturally occurring regulatory T cells display no abnormalities in activation induced cell death in NOD mice. PLOS One 2011; 6: e21630.
22. Arreaza G, Salojin K, Yang W, et al. Deficient activation and resistance to activation-induced apoptosis of CD8+ T cells is associated with defective peripheral tolerance in nonobese diabetic mice. Clin Immunol 2003; 107: 103-15
23. Decallonne B, van Etten E, Giulietti A, et al. Defect in activation induced cell death in non-obese diabetic (NOD) T lymphocytes. J Autoimmun 2003; 20: 219-26.
24. Yang W, Hussain S, Mi QS, Santamaria P, Delovitch TL. Perturbed homeostasis of peripheral T cells elicits decreased susceptibility to anti-CD3-induced apoptosis in prediabetic nonobese diabetic mice. J Immunol 2004; 173: 4407-16.
25. Yarkoni S, Kaminitz A, Sagiv Y, Askenasy N. Targeting of IL-2 receptor with a caspase fusion protein disrupts autoimmunity in prediabetic and diabetic NOD mice. Diabetologia 2010; 53: 356-68.
26. Yolcu ES, Ash S, Kaminitz A, Sagiv Y, Askenasy N, Yarkoni S. Apoptosis as a mechanism of T-regulatory cell homeostasis and suppression. Immunol Cell Biol 2008; 86: 650-8.
27. Elder ME, Maclaren NK. Identification of profound peripheral T lymphocyte immunodeficiencies in the spontaneously diabetic BB rat. J Immunol 1983; 130: 1723-31.
28. Guttmann RD, Colle E, Michel F, Seemayer T. Spontaneous diabetes mellitus syndrome in the rat. II. T lymphopenia and its association with clinical disease and pancreatic lymphocytic infiltration. J Immunol 1983; 130: 1732-5.
29. Hawkins T, Fuller J, Olson K, Speros S, Lernmark A. DR.lyp/lyp bone marrow maintains lymphopenia and promotes diabetes in lyp/lyp but not in +/+ recipient DR.lyp BB rats. J Autoimmun 2005; 25: 251-7.
30. Hernández-Hoyos G, Joseph S, Miller NG, Butcher GW. The lymphopenia mutation of the BB rat causes inappropriate apoptosis of mature thymocytes. Eur J Immunol 1999; 29: 1832-41.
31. Jung CG, Kamiyama T, Agui T. Elevated apoptosis of peripheral T lymphocytes in diabetic BB rats. Immunology 1999; 98: 590-4.
32. Hornum L, Rømer J, Markholst H. The diabetes-prone BB rat carries a frameshift mutation in Ian4, a positional candidate of Iddm1. Diabetes 2002; 51: 1972-9.
33. Rutledge EA, Fuller JM, Van Yserloo B, et al. Sequence variation and expression of the Gimap gene family in the BB rat. Exp Diabetes Res 2009; 2009: 835650.
34. Ramanathan S, Poussier P. T cell reconstitution of BB/W rats after the initiation of insulitis precipitates the onset of diabetes. J Immunol 1999; 162: 5134-42.
35. King C, Ilic A, Koelsch K, Sarvetnick N. Homeostatic expansion of T cells during immune insufficiency generates autoimmunity. Cell 2004; 117: 265-77.
36. Ramanathan S, Bihoreau MT, Paterson AD, Marandi L, Gauguier D, Poussier P. Thymectomy and radiation-induced type 1 diabetes in nonlymphopenic BB rats. Diabetes 2002; 51: 2975-81.
37. Zou L, Mendez F, Martin-Orozco N, Peterson EJ. Defective positive selection results in T cell lymphopenia and increased autoimmune diabetes in ADAP-deficient BDC2.5-C57BL/6 mice. Eur J Immunol 2008; 38: 986-94.
38. Gagnerault MC, Lanvin O, Pasquier V, et al. Autoimmunity during thymectomy-induced lymphopenia: role of thymus ablation and initial effector T cell activation timing in nonobese diabetic mice. J Immunol 2009; 183: 4913-20.
39. Stockinger B, Kassiotis G, Bourgeois C. Homeostasis and T cell regulation. Curr Opin Immunol 2004; 16: 775-9.
40. Baccala R, Theofilopoulos AN. The new paradigm of T-cell homeostatic proliferation-induced autoimmunity. Trends Immunol 2005; 26: 5-8.
41. Abbas AK, Lohr J, Knoechel B. Balancing autoaggressive and protective T cell responses. J Autoimmun 2007; 28: 59-61.
42. Gudmundsdottir H, Wells AD, Turka LA. Dynamics and requirements of T cell clonal expansion in vivo at the single-cell level: effector function is linked to proliferative capacity. J Immunol 1999; 162: 5212-23.
43. Goldrath AW, Bogatzki LY, Bevan MJ. Naive T cells transiently acquire a memory-like phenotype during homeostasis-driven proliferation. J Exp Med 2000; 192: 557-64.
44. Min B, Yamane H, Hu-Li J, Paul WE. Spontaneous and homeostatic proliferation of CD4 T cells are regulated by different mechanisms. J Immunol 2005; 174: 6039-44
45. La Gruta NL, Driel IR, Gleeson PA. Peripheral T cell expansion in lymphopenic mice results in a restricted T cell repertoire. Eur J Immunol 2000; 30: 3380-6.
46. Barthlott T, Kassiotis G, Stockinger B. T cell regulation as a side effect of homeostasis and competition. J Exp Med 2003; 197: 451-60.
47. Troy AE, Shen H. Cutting edge: homeostatic proliferation of peripheral T lymphocytes is regulated by clonal competition. J Immunol 2003; 170: 672-6.
48. Schrum AG, Turka LA. The proliferative capacity of individual naive CD4(+) T cells is amplified by prolonged T cell antigen receptor triggering. J Exp Med 2002; 196: 793-803.
49. Surh CD, Sprent J. Homeostatic T cell proliferation: how far can T cells be activated to self-ligands? J Exp Med 2000; 21: F9-F14.
50. Shklovskaya E, Fazekas de St. Groth B. Severely impaired clonal deletion of CD4+ T cells in low-dose irradiated mice: role of T cell antigen receptor and IL-7 receptor signals. J Immunol 2006; 177: 8320-30.
51. Le Campion A, Gagnerault MC, Auffray C, et al. Lymphopeniainduced spontaneous T-cell proliferation as a cofactor for autoimmune disease development. Blood 2009; 114: 1784-93.
52. Shvets A, Chakrabarti R, Gonzalez-Quintial R, Baccala R, Theofilopoulos AN, Prud'Homme GJ. Impaired negative regulation of homeostatically proliferating T cells. Blood 2009; 113: 622-5.
53. Serreze DV, Johnson EA, Chapman HD, et al. Autoreactive diabetogenic T-cells in NOD mice can efficiently expand from a greatly reduced precursor pool. Diabetes 2001; 50: 1992-2000.
54. Yaniv I, Ash S, Farkas DL, Askenasy N, Stein J. Consideration of strategies for hematopoietic cell transplantation. J Autoimmun 2009; 33: 255-9.
55. Askenasy EM, Askenasy N, Askenasy JJ. Does lymphopenia preclude restoration of immune homeostasis? The particular case of type 1 diabetes. Autoimmun Rev 2010; 9: 687-90.
56. Aly TA, Ide A, Humphrey K, et al. Genetic prediction of autoimmunity: initial oligogenic prediction of anti-islet autoimmunity amongst DR3/DR4-DQ8 relatives of patients with type 1A diabetes. J Autoimmun 2005; 25: 40-5.
57. Anaya JM, Castiblanco J, Tobon GJ, et al. Familial clustering of autoimmune diseases in patients with type 1 diabetes mellitus. J Autoimmun 2006; 26: 208-14.
58. Awdeh ZL, Yunis EJ, Audeh MJ, et al. A genetic explanation for the rising incidence of type 1 diabetes, a polygenic disease. J Autoimmun 2006; 27: 174-81.
59. Shimada A, Kanazawa Y, Motohashi Y, et al. Evidence for association between vitamin D receptor BsmI polymorphism and type 1 diabetes in Japanese. J Autoimmun 2008; 30: 207-11.
60. Neuhausen SL, Steele L, Ryan S, et al. Co-occurrence of celiac disease and other autoimmune diseases in celiacs and their firstdegree relatives. J Autoimmun 2008; 31: 160-5.
61. Shoenfeld Y, Selmi C, Zimlichman E, Gershwin ME. The autoimmunologist: geoepidemiology, a new center of gravity, and prime time for autoimmunity. J Autoimmun 2008; 31: 325-30.
62. Bach JF. Infections and autoimmune diseases. J Autoimmun 2005; 25(Suppl.): 74-80
63. Hewagama A, Richardson B. The genetics and epigenetics of autoimmune diseases. J Autoimmun 2009; 33: 3-11.
64. Borchers AT, Uibo R, Gershwin ME. The geoepidemiology of type 1 diabetes. Autoimmun Rev 2010; 9: 355-65.
65. Holland AM, Zakrzewski JL, Tsai JJ, et al. Extrathymic development of murine T cells after bone marrow transplantation. J Clin Invest 2012; 122: 4716-26.
66. Tanchot C, Le Campion A, Martin B, Léaument S, Dautigny N, Lucas B. Conversion of naive T cells to a memory-like phenotype in lymphopenic hosts is not related to a homeostatic mechanism that fills the peripheral naive T cell pool. J Immunol 2002; 168: 5042-6.
67. Walker LSK, Chodos A, Eggena M, Dooms H, Abbas AK. Antigen-dependent proliferation of CD4+CD25+ regulatory T cells in vivo. J Exp Med 2003; 198: 249-58
68. Stephens LA, Gray D, Anderton SM. CD4+CD25+ regulatory T cells limit the risk of autoimmune disease arising from T cell receptor crossreactivity. Proc Natl Acad Sci USA 2005; 102: 17418-23.
69. Tonkin DR, He J, Barbour G, Haskins K. Regulatory T cells prevent transfer of type 1 diabetes in NOD mice only when their antigen is present in vivo. J Immunol 2008; 181: 4516-22.
70. Kaminitz A, Mizrahi K, Yaniv I, Stein J, Askenasy N. Immunosuppressive therapy exacerbates autoimmunity in NOD mice and diminishes the protective activity of regulatory T cells. J Autoimmun 2010; 35: 145-52.
71. Kaminitz A, Yolcu ES, Mizrahi K, Shirwan H, Askenasy N. Killer regulatory T cells attenuate inflammatory insulitis in diabetic NOD mice through local and systemic immunomodulation. Int Immunol 2013; in press
72. Takaki T, Hosaka N, Miyake T, et al. Presence of donor-derived thymic epithelial cells in [B6/MRL/lpr] mice after allogeneic intrabone marrow-bone marrow transplantation (IBM-BMT). J Autoimmun 2008; 31: 408-15.
73. Muraro PA, Douek DC, Packer A, et al. Thymic output generates a new and diverse TCR repertoire after autologous stem cell transplantation in multiple sclerosis patients. J Exp Med 2005; 201: 805-16.
74. Zhang H, Chua KS, Guimond M, et al. Lymphopenia and interleukin-2 therapy alter homeostasis of CD4+CD25+ regulatory T cells. Nat Med 2005; 11: 1238-43.
75. Voltarelli JC, Couri CE, Stracieri AB, et al. Autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA 2007; 297: 1568-76.
76. Couri CE, Oliveira MC, Stracieri AB, et al. C-Peptide levels and insulin independence following autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA 2009; 301: 1573-9.
77. Snarski E, Milczarczyk A, Torosian T, et al. Independence of exogenous insulin following immunoablation and stem cell reconstitution in newly diagnosed diabetes type I. Bone Marrow Transplant 2011; 46: 562-6.
78. Zhang X, Ye L, Hu J, et al. Acute response of peripheral blood cell to autologous hematopoietic stem cell transplantation in type 1 diabetic patient. PLoS One 2012; 7: e31887.
79. Gu W, Hu J, Wang W, et al. Diabetic ketoacidosis at diagnosis influences complete remission after treatment with hematopoietic stem cell transplantation in adolescents with type 1 diabetes. Diabetes Care 2012; 35: 1413-9.
80. Li L, Shen S, Ouyang J, Hu Y, et al. Autologous hematopoietic stem cell transplantation modulates immunocompetent cells and improves β-cell function in Chinese patients with new onset of type 1 diabetes. J Clin Endocrinol Metab 2012; 97: 1729-36.
81. Zorina TD, Subbotin VM, Bertera S, et al. Recovery of the endogenous ß cell function in the NOD model of autoimmune diabetes. Stem Cells 2003; 21: 377-88.
82. Kang EM, Zickler PP, Burns S, et al. Hematopoietic stem cell transplantation prevents diabetes in NOD mice but does not contribute to significant islet cell regeneration once disease is established. Exp Hematol 2005; 33: 699-705.
83. Tian C, Ansari MJ, Paez-Cortez J, et al. Induction of robust diabetes resistance and prevention of recurrent type 1 diabetes following islet transplantation by gene therapy. J Immunol 2007; 179: 6762-9.
84. Askenasy EM, Askenasy N. Is autoimmune diabetes caused by aberrant immune activity or defective suppression of physiological self-reactivity? Autoimmun Rev 2013; 12: 633-7.
85. Iskovich S, Kaminitz A, Pearl-Yafe M, et al. Participation of adult bone marrow-derived stem cells in pancreatic regeneration: neogenesis versus endogenesis. Curr Stem Cell Res Ther 2007; 2: 272-9.
86. Wen Y, Ouyang J, Yang R, Chen J, Liu Y, Zhou X, Burt RK. Reversal of new-onset type 1 diabetes in mice by syngeneic bone marrow transplantation. Biochem Biophys Res Commun 2008; 374: 282-7.
87. Wen Y, Ouyang J, Li W, et al. Time point is important for effects of syngeneic bone marrow transplantation for type 1 diabetes in mice. Transplant Proc 2009; 41: 1801-7.
88. Larger E, Becourt C, Bach JF, Boitard C. Pancreatic islet beta-cells drive T-cell immune responses in the nonobese diabetic mouse model. J Exp Med 1996; 181: 1635-42.
89. Kaminitz A, Stein J, Yaniv I, Askenasy N. The vicious cycle of apoptotic B cell death in type 1 diabetes. Immunol Cell Biol 2007; 85: 582-9.
90. Pearl-Yafe M, Yolcu ES, Yaniv I, Stein J, Shirwan H, Askenasy N. The dual role of Fas-ligand as an injury effector and defense strategy in diabetes and islet transplantation. Bioessays 2006; 28: 211-22.
91. Ikehara S, Ohtsuki H, Good RA, et al. Prevention of type I diabetes in nonobese diabetic mice by allogeneic bone marrow transplantation. Proc Natl Acad Sci USA 1985; 82: 7743-7.
92. Colson YL, Li H, Boggs SS, Patrene KD, Johnson PC, Ildstad ST. Durable mixed allogeneic chimerism and tolerance by a nonlethal radiation-based cytoreductive approach. J Immunol 1996; 157: 2820-9.
93. Li H, Kaufman CL, Boggs SS, Johnson PC, Patrene KD, Ildstad ST. Mixed allogeneic chimerism induced by a sublethal approach prevents autoimmune diabetes and reverses insulitis in nonobese diabetic (NOD) mice. J Immunol 1996; 156: 380-8.
94. Kaufman CL, Li H, Ildstad ST. Patterns of hemopoietic reconstitution in nonobese diabetic mice: dichotomy of allogeneic resistance versus competitive advantage of disease-resistant marrow. J Immunol 1997; 158: 2435-42.
95. Nikolic B, Takeuchi Y, Leykin I, Fudaba Y, Smith RN, Sykes M. Mixed hematopoietic chimerism allows cure of autoimmune diabetes through allogeneic tolerance and reversal of autoimmunity. Diabetes 2004; 53: 376-83.
96. Elkin G, Prigozhina TB, Slavin S. Prevention of diabetes in nonobese diabetic mice by nonmyeloablative allogeneic bone marrow transplantation. Exp Hematol 2004; 32: 579-84.
97. Ildstad ST, Chilton PM, Xu H, Domenick MA, Ray MB. Preconditioning of NOD mice with anti-CD8 mAb and costimulatory blockade enhances chimerism and tolerance and prevents diabetes, while depletion of alpha beta-TCR? And CD4? cells negates the effect. Blood 2004; 105: 2577-84.
98. Zhang C, Todorov I, Lin CL, et al. Elimination of insulitis and augmentation of islet beta cell regeneration via induction of chimerism in overtly diabetic NOD mice. Proc Natl Acad Sci USA 2007; 104: 2337-42.
99. Verda L, Kim DA, Ikehara S, et al. Hematopoietic mixed chimerism derived from allogeneic embryonic stem cells prevents autoimmune diabetes mellitus in NOD mice. Stem Cells 2008; 26: 381-6
100. Shizuru JA, Weissman IL, Kernoff R, Masek M, Scheffold YC. Purified hematopoietic stem cell grafts induce tolerance to alloantigens and can mediate positive and negative T cell selection. Proc Natl Acad Sci USA 2000; 97: 9555-60.
101. Kishimoto H, Sprent J. A defect in central tolerance in NOD mice. Nat Immunol 2001; 2: 1025-31.
102. Lesage S, Hartley SB, Akkaraju S, Wilson J, Townsend M, Goodnow CC. Failure to censor forbidden clones of CD4 T cells in autoimmune diabetes. J Exp Med 2002; 196: 1175-88.
103. Brocker T, Riedinger M, Karjalainen K. Targeted expression of major histocompatibility complex (MHC) class II molecules demonstrates that dendritic cells can induce negative but not positive selection of thymocytes in vivo. J Exp Med 1997; 185: 541-50.
104. Nelson JL, Torrez R, Louie FM, Choe OS, Storb R, Sullivan KM. Pre-existing autoimmune disease in patients with long-term survival after allogeneic bone marrow transplantation. J Rheumatol Suppl 1997; 48: 23-9.
105. Burt RK, Testori A, Craig R, Cohen B, Suffit R, Barr W. Hematopoietic stem cell transplantation for autoimmune diseases: what have we learned? J Autoimmun 2008; 30: 116-20.
106. Deane S, Meyers FJ, Gershwin ME. On reversing the persistence of memory: hematopoietic stem cell transplant for autoimmune disease in the first ten years. J Autoimmun 2008; 30: 180-96.
107. Marmont AM. Will hematopoietic stem cell transplantation cure human autoimmune diseases? J Autoimmun 2008; 30: 145-50.
108. Okitsu T, Bartlett ST, Hadley GA, Drachenberg CB, Farney AC. Recurrent autoimmunity accelerates destruction of minor and major histoincompatible islet grafts in nonobese diabetic (NOD) mice. Am J Transplant 2001; 1: 138-45.
109. Makhlouf L, Kishimoto K, Smith RN, et al. The role of autoimmunity in islet allograft destruction: major histocompatibility complex class II matching is necessary for autoimmune destruction of allogeneic islet transplants after T-cell costimulatory blockade. Diabetes 2002; 51: 3202-10.
110. Kupfer TM, Crawford ML, Pham K, Gill RG. MHC-mismatched islet allografts are vulnerable to autoimmune recognition in vivo. J Immunol 2005; 175: 2309-16.
111. Vendrame F, Pileggi A, Laughlin E, et al. Recurrence of type 1 diabetes after simultaneous pancreas-kidney transplantation, despite immunosuppression, is associated with autoantibodies and pathogenic autoreactive CD4 T-cells. Diabetes 2010; 59: 947-57.